Editor’s Choice for May 2018

Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer

Phase I taselisib results and a cell-free DNA assay

Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099

A variety of approaches to measure the efficacy of PARP inhibitors

Development and clinical indications of PARP inhibitors

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL

Clinical development and economic prospects of CAR T cell immunotherapies

The best sequence of anti-HER2 therapy in metastatic breast cancer

ESO-ESMO-ABC guidelines in metastatic breast cancer

ESMO 2017 roundup with Dr Bishal Gyawali (2/2)

Editor's Choice for July 17